全文获取类型
收费全文 | 264454篇 |
免费 | 17435篇 |
国内免费 | 584篇 |
专业分类
耳鼻咽喉 | 3184篇 |
儿科学 | 8071篇 |
妇产科学 | 5650篇 |
基础医学 | 37949篇 |
口腔科学 | 10261篇 |
临床医学 | 20507篇 |
内科学 | 56213篇 |
皮肤病学 | 5740篇 |
神经病学 | 23733篇 |
特种医学 | 9365篇 |
外国民族医学 | 35篇 |
外科学 | 33288篇 |
综合类 | 1839篇 |
现状与发展 | 1篇 |
一般理论 | 154篇 |
预防医学 | 29008篇 |
眼科学 | 4760篇 |
药学 | 15992篇 |
中国医学 | 860篇 |
肿瘤学 | 15863篇 |
出版年
2023年 | 1185篇 |
2022年 | 1095篇 |
2021年 | 4483篇 |
2020年 | 3469篇 |
2019年 | 4955篇 |
2018年 | 6708篇 |
2017年 | 5221篇 |
2016年 | 5157篇 |
2015年 | 5904篇 |
2014年 | 8131篇 |
2013年 | 10438篇 |
2012年 | 16155篇 |
2011年 | 16800篇 |
2010年 | 8549篇 |
2009年 | 8154篇 |
2008年 | 13690篇 |
2007年 | 14437篇 |
2006年 | 13559篇 |
2005年 | 13626篇 |
2004年 | 12382篇 |
2003年 | 11446篇 |
2002年 | 9143篇 |
2001年 | 8429篇 |
2000年 | 8403篇 |
1999年 | 7387篇 |
1998年 | 2583篇 |
1997年 | 2089篇 |
1996年 | 2148篇 |
1995年 | 1993篇 |
1994年 | 1924篇 |
1993年 | 1756篇 |
1992年 | 4852篇 |
1991年 | 4468篇 |
1990年 | 4203篇 |
1989年 | 4027篇 |
1988年 | 3669篇 |
1987年 | 3358篇 |
1986年 | 3133篇 |
1985年 | 3007篇 |
1984年 | 2155篇 |
1983年 | 1795篇 |
1982年 | 996篇 |
1981年 | 879篇 |
1980年 | 822篇 |
1979年 | 1647篇 |
1978年 | 1051篇 |
1977年 | 840篇 |
1975年 | 847篇 |
1974年 | 896篇 |
1973年 | 888篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Jos B. Poell Leon J. Wils Arjen Brink Ralf Dietrich Christine Krieg Eunike Velleuer Ilkay Evren Elisabeth R. Brouns Jan G. de Visscher Elisabeth Bloemena Bauke Ylstra Ruud H. Brakenhoff 《International journal of cancer. Journal international du cancer》2023,152(2):227-238
Oral squamous cell carcinomas (OSCCs) develop in genetically altered epithelium in the mucosal lining, also coined as fields, which are mostly not visible but occasionally present as white oral leukoplakia (OL) lesions. We developed a noninvasive genetic assay using next-generation sequencing (NGS) on brushed cells to detect the presence of genetically altered fields, including those that are not macroscopically visible. The assay demonstrated high accuracy in OL patients when brush samples were compared with biopsies as gold standard. In a cohort of Fanconi anemia patients, detection of mutations in prospectively collected oral brushes predicted oral cancer also when visible abnormalities were absent. We further provide insight in the molecular landscape of OL with frequent changes of TP53, FAT1 and NOTCH1. NGS analysis of noninvasively collected samples offers a highly accurate method to detect genetically altered fields in the oral cavity, and predicts development of OSCC in high-risk individuals. Noninvasive genetic screening can be employed to screen high-risk populations for cancer and precancer, map the extension of OL lesions beyond what is visible, map the oral cavity for precancerous changes even when visible abnormalities are absent, test accuracy of promising imaging modalities, monitor interventions and determine genetic progression as well as the natural history of the disease in the human patient. 相似文献
2.
Edwin van der Pol Joshua A. Welsh Rienk Nieuwland 《Journal of thrombosis and haemostasis》2022,20(1):245-251
The Extracellular Vesicle Flow Cytometry Working Group ( http://www.evflowcytometry.org ) is formed by members of the International Society for Extracellular Vesicles (ISEV), the International Society for Advancement of Cytometry (ISAC), and the International Society on Thrombosis and Haemostasis (ISTH). This working group of flow cytometry experts develops guidelines for best practices regarding flow cytometry detection of extracellular vesicles. To improve rigor and standardization, this working group published a framework outlining the minimal information to report about a flow cytometry experiment on extracellular vesicles (MIFlowCyt-EV) in the Journal of Extracellular Vesicles, the ISEV journal, in 2020. In parallel, an article explaining MIFlowCyt-EV was published in Cytometry Part A, one of the ISAC journals, and now will be introduced to the ISTH as an SSC Communication in the Journal of Thrombosis and Haemostasis. The goal of this SSC Communication is to explain why flow cytometry is becoming the instrument of choice to characterize single extracellular vesicles, the obstacles that have been identified and (mostly) overcome by developing procedures to calibrate flow cytometers, and the relevance of reporting minimal information to improve reliability and reproducibility of experiments in which flow cytometers are used for characterization of extracellular vesicles. 相似文献
3.
de Souza Gabriel Hernandez Machado Pandolfo Mariana Travi Bortoluzzi Eduardo Antunes da Silveira Teixeira Cleonice Rossetto Hebert Luís da Rosa Amanda Freitas Machado Renata Gondo da Fonseca Roberti Garcia Lucas 《Odontology / the Society of the Nippon Dental University》2022,110(3):535-544
Odontology - The purpose of this study was to investigate whether the root perforation repair with mineral aggregate-based cements affects the retention of customized fiberglass posts to bovine... 相似文献
4.
5.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
6.
7.
8.
9.
Two-year results after combined phacoemulsification and iris-fixated phakic intraocular lens removal
Gaurisankar Zoraida Solaiga van Rijn Gwyneth A. Cheng Yanny Y. Y. Luyten Gregorius P. M. Beenakker Jan-Willem M. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(4):1367-1375
Graefe's Archive for Clinical and Experimental Ophthalmology - To describe and present results after a technique for cataract surgery combined with explantation of an iris-fixated phakic... 相似文献
10.
Kely Paviani StevanatoRaíssa Bocchi PedrosoCatia Millene Dell AgnoloLander Dos SantosFernando Castilho PellosoMaria Dalva de Barros CarvalhoSandra Marisa Pelloso 《Asian Pacific journal of cancer prevention》2022,23(4):1117-1123
Objective: To perform a scoping review of the applicability of the Gail model in different countries for different ethnicities. Methods: The review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist and search strategies based on the PICOS approach. The reviewed articles were included if they were published between 2013 and 2018 in English, Portuguese, or Spanish; were original articles available in full online; and described the use of the Gail model. The PubMed, Embase, and Web of Science data bases were searched. Results: A total of 38 articles eligible for analysis were identified, of which 16 used the Gail model to assess breast cancer risk in women, eight analyzed the applicability of this tool in their population, seven compared the tool and/or modified it according to the specific risk factors of their population, and seven cited the model in determining eligibility for chemoprevention. Conclusion: The Gail model has different applicabilities Greater effectiveness and breast cancer risk are found in developed countries. 相似文献